R-CHOP Regimen Initiation and Management

Patient Assessment and Risk Stratification

The European Society for Medical Oncology recommends calculating the International Prognostic Index (IPI) or age-adjusted IPI (aaIPI) to determine risk category and guide treatment intensity in patients with diffuse large B-cell lymphoma 1, 2
Assessment of cardiac function with left ventricular ejection fraction (LVEF) measurement is necessary before doxorubicin administration in patients with diffuse large B-cell lymphoma 2
Screening for hepatitis B and C, and HIV is required as these conditions necessitate specific management during rituximab therapy 1, 3
Obtaining complete blood count, lactate dehydrogenase (LDH), and uric acid levels is essential to assess tumor burden and tumor lysis syndrome risk in patients with diffuse large B-cell lymphoma 3, 4

The European Society for Medical Oncology suggests administering oral prednisone for several days as "prephase" treatment before starting full R-CHOP to prevent tumor lysis syndrome in patients with high tumor load 5, 1

For young patients (≤60 years) with low-risk diffuse large B-cell lymphoma, the European Society for Medical Oncology recommends administering 6 cycles of R-CHOP-21 with 6 doses of rituximab 1, 2
For young patients (≤60 years) with low-intermediate risk or low-risk with bulky disease, the European Society for Medical Oncology suggests administering 6 cycles of R-CHOP-21 with radiotherapy to sites of previous bulky disease 5, 1, 2
For elderly patients (60-80 years) with diffuse large B-cell lymphoma, the European Society for Medical Oncology recommends administering 6-8 cycles of R-CHOP-21 with 8 doses of rituximab every 21 days 1, 6, 3, 2

The European Society for Medical Oncology advises against dose reductions due to hematological toxicity in patients treated with curative intent, and instead recommends using prophylactic granulocyte colony-stimulating factor (G-CSF) 5, 1, 3, 2
Vincristine dose should be capped at 2 mg maximum regardless of body surface area due to neurotoxicity concerns 7
Full weight-based dosing for all chemotherapy agents should be used in obese patients without arbitrary caps or reductions (except vincristine) 7

The European Society for Medical Oncology recommends initiating PCP prophylaxis with sulfamethoxazole/trimethoprim, herpes virus prophylaxis with acyclovir, and irradiating all blood products on day 1 of treatment 7

The European Society for Medical Oncology suggests administering CNS prophylaxis for patients with high-intermediate or high-risk IPI, >1 extranodal site, or elevated LDH 5, 1, 6, 3, 2
Intravenous high-dose methotrexate should be used for CNS prophylaxis, as intrathecal methotrexate alone is probably not optimal 1, 6, 3, 2

The European Society for Medical Oncology (ESMO) 2015 guideline states that dose‑dense R‑CHOP given every 14 days provides no survival advantage over the standard 21‑day schedule in diffuse large B‑cell lymphoma. 8
A pivotal randomized British trial of 1,080 patients with a median follow‑up of 46 months showed no significant difference in 2‑year overall survival (82.7 % vs 80.8 %; HR 0.90, p = 0.38) or 2‑year progression‑free survival (75.4 % vs 74.8 %; HR 0.94, p = 0.59) between R‑CHOP‑14 and R‑CHOP‑21. Level I evidence. 9
Subgroup analyses revealed that no molecular or clinical subgroup—including younger high‑risk patients—derived benefit from dose intensification with R‑CHOP‑14. Level I evidence. 9
Consequently, R‑CHOP‑14 should not be used as first‑line therapy for diffuse large B‑cell lymphoma because it does not improve overall survival or progression‑free survival. Level I evidence. [8][9]10

Patients aged 60–80 years: administer 6–8 cycles of R‑CHOP‑21, delivering eight rituximab infusions every 21 days. [8][9]10
Young patients with low‑risk disease (aa‑IPI = 0): give 6 cycles of R‑CHOP‑21 with six rituximab infusions. 8

Tumor‑lysis‑syndrome prophylaxis: for patients with high tumor burden, give oral prednisolone 100 mg daily for 5–7 days before initiating full chemotherapy. [8][10]
Prophylactic G‑CSF: recommended for patients > 60 years and for any patient receiving curative‑intent therapy to prevent febrile neutropenia and avoid dose reductions. [8][10]
Baseline cardiac assessment: measure left‑ventricular ejection fraction before starting anthracycline (doxorubicin). 8
Viral screening: test for hepatitis B, hepatitis C, and HIV prior to rituximab administration. 8

Indications for CNS prophylaxis (per ESMO 2015): high or intermediate‑high IPI, involvement of more than one extranodal site, elevated LDH, or disease affecting the testis, kidney, or adrenal glands. [8][9]
Preferred method: high‑dose intravenous methotrexate; intrathecal methotrexate alone is considered suboptimal. [8][9]

Avoid dose reductions for hematologic toxicity whenever possible; use prophylactic G‑CSF instead of lowering chemotherapy intensity. [8][10]
Maintain dose intensity because reductions are associated with significantly poorer outcomes (as emphasized in guideline statements). 8

The totality of Level I evidence and the 2015 ESMO guideline confirm that R‑CHOP‑14 does not improve clinical outcomes and should not be selected under the assumption of superiority. [8][9]